Skip to main content
VALIRX PLC logo

VALIRX PLC — Investor Relations & Filings

Ticker · VAL ISIN · GB00BLH13C52 LEI · 213800VQKB9SJCQDET40 IL Professional, scientific and technical activities
Open in API
Filings indexed 575 across all filing types
Latest filing 2026-05-15 Capital/Financing Update
Country GB United Kingdom
Listing IL VAL

About VALIRX PLC

https://www.valirx.com/

ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.

Recent filings

Filing Released Lang Actions
Fundraising of up to £1,155,000
Capital/Financing Update Classification · 87% confidence The document is a Regulatory News Service (RNS) announcement by ValiRx PLC detailing a fundraising of up to £1,155,000 via a placing, direct subscription, retail offer and associated warrants, including terms and conditions and expected admission date. It focuses on new share issuance, capital structure, and financing activities. This clearly falls under “Capital/Financing Update” rather than a full annual or interim report, governance document, or dividend notice.
2026-05-15 English
Change of Registered Office
Regulatory Filings Classification · 90% confidence The document is a short RNS announcement informing investors of an administrative change (change of registered office address). It is not a full report, not a board or management change, and does not fit more specific categories such as dividend notice, share issue, or financial report. Therefore it falls into the general regulatory announcements/fallback category.
2026-03-31 English
ValiRx Commercial Update Q1 2026
Regulatory Filings Classification · 78% confidence The document is an RNS announcement titled “ValiRx Commercial Update Q1 2026.” It provides an operational and commercial progress update (pipeline agreements, cost savings, subsidiary formation, grant awards) rather than a formal financial earnings release, interim report, or detailed annual report. It is issued via the London Stock Exchange’s RNS service and does not include statutory financial statements or reference to an attached full report. This fits the “Regulatory Filings” fallback category (RNS).
2026-03-26 English
ValiRx and TwinEdge to present Digital Twin data
Regulatory Filings Classification · 75% confidence The document is an RNS press release on the London Stock Exchange by ValiRx PLC announcing the presentation of scientific abstracts and articles, conference participation, and publication details. It contains no financial results, board changes, share issues, dividends, or other specific corporate actions. It is a general regulatory news announcement that does not fit any specialized filing category, making it a fallback Regulatory Filing (RNS).
2026-03-24 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official announcement regarding a share purchase by the Chief Executive Officer (Mark Eccleston) of ValiRx PLC. It explicitly includes the 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR) form, which is the standard regulatory requirement for reporting insider trades. This falls directly under the 'Director's Dealing' category.
2026-03-04 English
ValiRx forms ValiRx Animal Health Ltd subsidiary
Regulatory Filings Classification · 98% confidence The document is a regulatory announcement distributed via the London Stock Exchange's RNS (Regulatory News Service). It details a specific corporate development: the incorporation of a new subsidiary, 'ValiRx Animal Health Limited'. This type of announcement regarding company operations and strategic updates that do not fall into specific categories like M&A, dividends, or financial reports is best classified as a general regulatory filing.
2026-03-02 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.